egfr-mutant lung cancer cells have a unique response to anti-pd-l1 antibodies
Published 1 year ago • 113 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
0:37
response to systemic anti-cancer therapy in uncommon egfr mutations
-
14:24
egfr-mutant lung cancer & treatment options | 2023 living with egfr-mutant lung cancer patient forum
-
45:43
egfr mutant lung cancer: 2013 update
-
20:38
future research and treatment options | 2023 living with egfr-mutant lung cancer patient forum
-
5:06
case based panel discussion - egfr mutation and high pdl1 - what is the role of immunotherapy in tre
-
58:47
15 years of advances in egfr mutant lung cancer
-
4:25
do immune checkpoint inhibitors work in egfr mutant lung cancer?
-
1:18:11
management of egfr-mutant lung cancer with central nervous system metastases
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
52:27
immunotherapy/checkpoint inhibitor, targeted immunotherapy drugs 5/2/18
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
0:48
current role of immunotherapy in egfr-mutant lung cancer
-
20:34
2021 west oncology | lung cancer | egfr mutation therapy resistance and adcs and trop2
-
14:30
adjuvant therapy for egfr mutant nsclc
-
2:36
atezolizumab with erlotinib in combination treatment for egfr mutant nsclc
-
4:14
case based panel discussion - egfr and high pdl1 what is the role of immunotherapy in treatment?
-
19:59
biologic basis of immunotherapy in lung cancer
-
1:57
targeting pd-1 and pd-l1 for lung cancer therapy